Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma

NCT01029873 is registered in ClinicalTrials.gov with Altor BioScience as lead sponsor.

NCT NCT01029873
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01029873 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Lead sponsor
Altor BioScience
Phase
Phase 1/2
Overall status
Terminated
Start date
February 28, 2010
Completion date
September 30, 2013
Enrollment
22 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma